CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space tech co. rolls out futuristic lunar rover for NASA's Artemis missions

to the moon

Houston-based space exploration company Intuitive Machines just unveiled its version of a lunar terrain vehicle that’s designed to be used by astronauts in NASA’s Artemis moon discovery program.

Intuitive Machine recently rolled out its RACER lunar terrain vehicle (LTV) at Space Center Houston. RACER stands for Reusable Autonomous Crewed Exploration Rover.

The rover can accommodate two astronauts and nearly 900 pounds of cargo. In addition, it can pull a trailer loaded with almost 1,800 pounds of cargo.

Intuitive Machines will retain ownership and operational capabilities that will enable remote operation of the LTV between Artemis missions for about 10 years.

NASA chose Intuitive Machines and two other companies to develop advanced LTV capabilities.

“The objective is to enable Artemis astronauts, like the Apollo-era moonwalkers before them, to drive the rover, which features a rechargeable electric battery and a robotic arm, across the lunar surface, to conduct scientific research and prepare for human missions to Mars,” Intuitive Machines says in a post on its website.

The company tapped the expertise of Apollo-era moonwalkers Charlie Duke and Harrison Schmitt to design the pickup-truck-sized RACER. Intuitive Machines engineered the LTV in partnership with Atlas Devices, AVL, Barrios, Boeing, CSIRO, FUGRO, Michelin, Northrop Grumman, and Roush.

“This [project] strategically aligns with the Company’s flight-proven capability to deliver payloads to the surface of the Moon under [NASA’s] Commercial Lunar Payload Services initiative, further solidifying our position as a proven commercial contractor in lunar exploration,” says Steve Altemus, CEO of Intuitive Machines.

Astronauts at NASA’s Johnson Space Center are testing the static prototype of the company’s LTV. Meanwhile, the fully electric mobile demonstration LTV will undergo field testing later this month near Meteor Crater National Park in Arizona.

NASA expects to choose an LTV provider or providers in 2025.

- YouTubewww.youtube.com

Houston accelerator names inaugural cohort to propel digital transformation in energy

building tech

Houston-based Venture Builder VC has kicked off its NOV Supernova Accelerator and named its inaugural cohort.

The program, originally announced earlier this year, focuses on accelerating digital transformation solutions for NOV Inc.'s operations in the upstream oil and gas industry. It will support high-potential startups in driving digital transformation within the energy sector, specifically upstream oil and gas, and last five months and culminate in a demo day where founders will present solutions to industry leaders, potential investors, NOV executives, and other stakeholders.

The NOV Supernova Accelerator will work to cultivate relationships between startups and NOV. They will offer specific companies access to NOV’s corporate R&D teams and business units to test their solutions in an effort to potentially develop long-term partnerships.

“The Supernova Accelerator is a reflection of our commitment to fostering forward-thinking technologies that will drive the future of oil and gas,” Diana Grauer, director of R&D of NOV, says in a news release.

The cohort’s focus will be digital transformation challenges that combine with NOV’s vision and include data management and analytics, operational efficiency, HSE (Health, Safety, and Environmental) monitoring, predictive maintenance, and digital twins.

Startups selected for the program include:

  • AnyLog, an edge data management platform that replaces proprietary edge projects with a plug-and-play solution that services real-time data directly at the source, eliminating cloud costs, data transfer, and latency issues.
  • Equipt, an AI-powered self-serve platform that maximizes Asset & Field Service performance, and minimizes downtime and profit leakages.
  • Geolumina's platform is a solution that leverages data analytics to enhance skills, scale insights, and improve efficiency for subsurface companies.
  • Gophr acts as the "Priceline" of logistics, using AI to provide instant shipping quotes and optimize dispatch for anything from paper clips to rocket ships.
  • IoT++ simplifies industrial IoT with a secure, AI-enabled ecosystem of plug-and-play edge devices.
  • Kiana's hardware-agnostic solution secures people, assets, and locations using existing Wi-Fi, Bluetooth, UWB, and cameras, helping energy and manufacturing companies reduce risks and enhance operations.
  • Novity uses AI and physics models to accurately predict machine faults, helping factory operators minimize downtime by knowing the remaining useful life of their machines.
  • Promecav is redefining crude oil conditioning with patented technology that slashes water use and energy while reducing toxic exposure for safer, cleaner, and more sustainable oil processing.
  • RaftMind's enterprise AI solution transforms how businesses manage knowledge. Our advanced platform makes it easier to process data and unlock insights from diverse sources.
  • Spindletop AI uses edge-based machine learning to make each well an autonomous, self-optimizing unit, cutting costs, emissions, and cloud dependence.
  • Taikun.aicombines generative AI with SCADA data to create virtual industrial engineers, augmenting human teams for pennies an hour.
  • Telemetry Insight’s platform utilizes high-resolution accelerometer data to simplify oilfield monitoring and optimize marginal wells for U.S. oil and gas producers via actionable insights.
  • Visual Logging utilizes fiber optic and computer vision technology to deliver real-time monitoring solutions, significantly enhancing data accuracy by providing precise insights into well casing integrity and flow conditions.

“Each startup brings unique solutions to the table, and we are eager to see how these technologies will evolve with NOV’s support and expertise,” Billy Grandy, general partner of Venture Builder VC, says in the release. “This partnership reflects our ongoing commitment to nurturing talent and driving innovation within the energy sector.”

Venture Builder VC is a consulting firm, investor, and accelerator program.

“Unlike mergers and acquisitions, the venture client model allows corporations like NOV to quickly test and implement new technologies without committing to an acquisition or risking significant investment,” Grandy previously said about the accelerator program.

------

This article originally ran on EnergyCapital.